Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen Secures $10M in Equity, $5M Bridge Loan, Appoints Interim CEO

NEW YORK, April 4 - Existing institutional investors of Deltagen have agreed to purchase $10 million of the company's preferred stock in a private placement, Deltagen said today.

 

The same investors have committed to a bridge loan of $5 million, at an annual interest of 10 percent, that can be increased to $6 million.

 

In addition, Joseph Limber, former president and CEO of Aclara BioSciences, has become Deltagen's interim CEO and will move on to be president and CEO after the closing of the financing. Richard Hawkins, Deltagen's CFO, is expected to leave the company before the end of the month.

 

The financing will enable Deltagen to expand its product range and start new marketing and sales initiatives, according to the company. It is subject to shareholder approval and the satisfaction of certain closing conditions. Deltagen's stockholders will also be asked to approve a reverse stock split.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.